guest ::
| Home > Publications Database > Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia. > print |
| Home > Publications Database > Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia. > print |
| 001 | 272822 | ||
| 005 | 20250127091625.0 | ||
| 024 | 7 | _ | |a pmc:PMC11490412 |2 pmc |
| 024 | 7 | _ | |a 10.1002/mds.29960 |2 doi |
| 024 | 7 | _ | |a pmid:39132902 |2 pmid |
| 024 | 7 | _ | |a 0885-3185 |2 ISSN |
| 024 | 7 | _ | |a 1531-8257 |2 ISSN |
| 024 | 7 | _ | |a altmetric:166251201 |2 altmetric |
| 037 | _ | _ | |a DZNE-2024-01240 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Sosero, Yuri L |b 0 |
| 245 | _ | _ | |a Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia. |
| 260 | _ | _ | |a New York, NY |c 2024 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1729494933_2184 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Levodopa-induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including GBA1 and LRRK2.Our goal was to investigate the effects of genetic variants on risk and time to LID.We performed a genome-wide association study (GWAS) and analyses focused on GBA1 and LRRK2 variants. We also calculated polygenic risk scores (PRS) including risk variants for PD and variants in genes involved in the dopaminergic transmission pathway. To test the influence of genetics on LID risk we used logistic regression, and to examine its impact on time to LID we performed Cox regression including 1612 PD patients with and 3175 without LID.We found that GBA1 variants were associated with LID risk (odds ratio [OR] = 1.65; 95% confidence interval [CI], 1.21-2.26; P = 0.0017) and LRRK2 variants with reduced time to LID onset (hazard ratio [HR] = 1.42; 95% CI, 1.09-1.84; P = 0.0098). The fourth quartile of the PD PRS was associated with increased LID risk (ORfourth_quartile = 1.27; 95% CI, 1.03-1.56; P = 0.0210). The third and fourth dopamine pathway PRS quartiles were associated with a reduced time to development of LID (HRthird_quartile = 1.38; 95% CI, 1.07-1.79; P = 0.0128; HRfourth_quartile = 1.38; 95% CI = 1.06-1.78; P = 0.0147).This study suggests that variants implicated in PD and in the dopaminergic transmission pathway play a role in the risk/time to develop LID. Further studies will be necessary to examine how these findings can inform clinical care. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| 536 | _ | _ | |a 354 - Disease Prevention and Healthy Aging (POF4-354) |0 G:(DE-HGF)POF4-354 |c POF4-354 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a GBA1 |2 Other |
| 650 | _ | 7 | |a LRRK2 |2 Other |
| 650 | _ | 7 | |a Parkinson's disease |2 Other |
| 650 | _ | 7 | |a dopamine |2 Other |
| 650 | _ | 7 | |a levodopa‐induced dyskinesia |2 Other |
| 650 | _ | 7 | |a Levodopa |0 46627O600J |2 NLM Chemicals |
| 650 | _ | 7 | |a Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |0 EC 2.7.11.1 |2 NLM Chemicals |
| 650 | _ | 7 | |a Glucosylceramidase |0 EC 3.2.1.45 |2 NLM Chemicals |
| 650 | _ | 7 | |a LRRK2 protein, human |0 EC 2.7.11.1 |2 NLM Chemicals |
| 650 | _ | 7 | |a Dopamine |0 VTD58H1Z2X |2 NLM Chemicals |
| 650 | _ | 7 | |a GBA protein, human |0 EC 3.2.1.45 |2 NLM Chemicals |
| 650 | _ | 7 | |a Antiparkinson Agents |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Levodopa: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Dyskinesia, Drug-Induced: genetics |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Leucine-Rich Repeat Serine-Threonine Protein Kinase-2: genetics |2 MeSH |
| 650 | _ | 2 | |a Glucosylceramidase: genetics |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Genome-Wide Association Study |2 MeSH |
| 650 | _ | 2 | |a Dopamine: metabolism |2 MeSH |
| 650 | _ | 2 | |a Antiparkinson Agents: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Genetic Predisposition to Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Polymorphism, Single Nucleotide: genetics |2 MeSH |
| 700 | 1 | _ | |a Bandres-Ciga, Sara |0 0000-0003-0056-1361 |b 1 |
| 700 | 1 | _ | |a Ferwerda, Bart |b 2 |
| 700 | 1 | _ | |a Tocino, Maria T P |b 3 |
| 700 | 1 | _ | |a Belloso, Dìaz R |b 4 |
| 700 | 1 | _ | |a Gómez-Garre, Pilar |0 0000-0003-1550-6218 |b 5 |
| 700 | 1 | _ | |a Faouzi, Johann |b 6 |
| 700 | 1 | _ | |a Taba, Pille |b 7 |
| 700 | 1 | _ | |a Pavelka, Lukas |b 8 |
| 700 | 1 | _ | |a Marques, Tainà M |b 9 |
| 700 | 1 | _ | |a Gomes, Clarissa P C |b 10 |
| 700 | 1 | _ | |a Kolodkin, Alexey |b 11 |
| 700 | 1 | _ | |a May, Patrick |0 0000-0001-8698-3770 |b 12 |
| 700 | 1 | _ | |a Milanowski, Lukasz M |b 13 |
| 700 | 1 | _ | |a Wszolek, Zbigniew K |0 0000-0001-5487-1053 |b 14 |
| 700 | 1 | _ | |a Uitti, Ryan J |b 15 |
| 700 | 1 | _ | |a Heutink, Peter |0 P:(DE-2719)2810728 |b 16 |u dzne |
| 700 | 1 | _ | |a van Hilten, Jacobus J |b 17 |
| 700 | 1 | _ | |a Simon, David K |0 0000-0003-4793-0574 |b 18 |
| 700 | 1 | _ | |a Eberly, Shirley |b 19 |
| 700 | 1 | _ | |a Alvarez, Ignacio |b 20 |
| 700 | 1 | _ | |a Krohn, Lynne |b 21 |
| 700 | 1 | _ | |a Yu, Eric |b 22 |
| 700 | 1 | _ | |a Freeman, Kathryn |b 23 |
| 700 | 1 | _ | |a Rudakou, Uladzislau |b 24 |
| 700 | 1 | _ | |a Ruskey, Jennifer A |b 25 |
| 700 | 1 | _ | |a Asayesh, Farnaz |b 26 |
| 700 | 1 | _ | |a Menéndez-Gonzàlez, Manuel |b 27 |
| 700 | 1 | _ | |a Pastor, Pau |b 28 |
| 700 | 1 | _ | |a Ross, Owen A |0 0000-0003-4813-756X |b 29 |
| 700 | 1 | _ | |a Krüger, Rejko |b 30 |
| 700 | 1 | _ | |a Consortium, NCER-PD |b 31 |e Collaboration Author |
| 700 | 1 | _ | |a Corvol, Jean-Christophe |0 0000-0001-7325-0199 |b 32 |
| 700 | 1 | _ | |a Koks, Sulev |0 0000-0001-6087-6643 |b 33 |
| 700 | 1 | _ | |a Mir, Pablo |0 0000-0003-1656-302X |b 34 |
| 700 | 1 | _ | |a De Bie, Rob M A |0 0000-0001-5267-0784 |b 35 |
| 700 | 1 | _ | |a Iwaki, Hirotaka |0 0000-0002-8982-7885 |b 36 |
| 700 | 1 | _ | |a Gan-Or, Ziv |0 0000-0003-0332-234X |b 37 |
| 700 | 1 | _ | |a Consortium, International Parkinson's Disease Genomic |b 38 |e Collaboration Author |
| 700 | 1 | _ | |a Acharya, Geeta |b 39 |e Contributor |
| 700 | 1 | _ | |a Aguayo, Gloria |b 40 |e Contributor |
| 700 | 1 | _ | |a Alexandre, Myriam |b 41 |e Contributor |
| 700 | 1 | _ | |a Ali, Muhammad |b 42 |e Contributor |
| 700 | 1 | _ | |a Ammerlann, Wim |b 43 |e Contributor |
| 700 | 1 | _ | |a Arena, Giuseppe |b 44 |e Contributor |
| 700 | 1 | _ | |a Balling, Rudi |b 45 |e Contributor |
| 700 | 1 | _ | |a Bassis, Michele |b 46 |e Contributor |
| 700 | 1 | _ | |a Beaumont, Katy |b 47 |e Contributor |
| 700 | 1 | _ | |a Becker, Regina |b 48 |e Contributor |
| 700 | 1 | _ | |a Bellora, Camille |b 49 |e Contributor |
| 700 | 1 | _ | |a Berchem, Guy |b 50 |e Contributor |
| 700 | 1 | _ | |a Berg, Daniela |b 51 |e Contributor |
| 700 | 1 | _ | |a Bisdorff, Alexandre |b 52 |e Contributor |
| 700 | 1 | _ | |a Boussaad, Ibrahim |b 53 |e Contributor |
| 700 | 1 | _ | |a Brockmann, Kathrin |0 P:(DE-2719)2811916 |b 54 |e Contributor |u dzne |
| 700 | 1 | _ | |a Calme, Jessica |b 55 |e Contributor |
| 700 | 1 | _ | |a Castillo, Lorieza |b 56 |e Contributor |
| 700 | 1 | _ | |a Contesotto, Gessica |b 57 |e Contributor |
| 700 | 1 | _ | |a Diederich, Nico |b 58 |e Contributor |
| 700 | 1 | _ | |a Dondelinger, Rene |b 59 |e Contributor |
| 700 | 1 | _ | |a Esteves, Daniela |b 60 |e Contributor |
| 700 | 1 | _ | |a Fagherazzi, Guy |b 61 |e Contributor |
| 700 | 1 | _ | |a Ferrand, Jean-Yves |b 62 |e Contributor |
| 700 | 1 | _ | |a Gantenbein, Manon |b 63 |e Contributor |
| 700 | 1 | _ | |a Gasser, Thomas |0 P:(DE-2719)2320009 |b 64 |e Contributor |u dzne |
| 700 | 1 | _ | |a Gawron, Piotr |b 65 |e Contributor |
| 700 | 1 | _ | |a Ghosh, Soumyabrata |b 66 |e Contributor |
| 700 | 1 | _ | |a Giraitis, Marijus |b 67 |e Contributor |
| 700 | 1 | _ | |a Glaab, Enrico |b 68 |e Contributor |
| 700 | 1 | _ | |a De Lope, Elisa Gómez |b 69 |e Contributor |
| 700 | 1 | _ | |a Graas, Jérôme |b 70 |e Contributor |
| 700 | 1 | _ | |a Graziano, Mariella |b 71 |e Contributor |
| 700 | 1 | _ | |a Groues, Valentin |b 72 |e Contributor |
| 700 | 1 | _ | |a Grünewald, Anne |b 73 |e Contributor |
| 700 | 1 | _ | |a Gu, Wei |b 74 |e Contributor |
| 700 | 1 | _ | |a Hammot, Gaël |b 75 |e Contributor |
| 700 | 1 | _ | |a Hanff, Anne-Marie |b 76 |e Contributor |
| 700 | 1 | _ | |a Hansen, Linda |b 77 |e Contributor |
| 700 | 1 | _ | |a Heneka, Michael |0 P:(DE-2719)2000008 |b 78 |e Contributor |u dzne |
| 700 | 1 | _ | |a Henr, Estelle |b 79 |e Contributor |
| 700 | 1 | _ | |a Herbrink, Sylvia |b 80 |e Contributor |
| 700 | 1 | _ | |a Herzinger, Sascha |b 81 |e Contributor |
| 700 | 1 | _ | |a Heymann, Michael |b 82 |e Contributor |
| 700 | 1 | _ | |a Hu, Michele |b 83 |e Contributor |
| 700 | 1 | _ | |a Hundt, Alexander |b 84 |e Contributor |
| 700 | 1 | _ | |a Jacoby, Nadine |b 85 |e Contributor |
| 700 | 1 | _ | |a Lebioda, Jacek Jaroslaw |b 86 |e Contributor |
| 700 | 1 | _ | |a Jaroz, Yohan |b 87 |e Contributor |
| 700 | 1 | _ | |a Jónsdóttir, Sonja |b 88 |e Contributor |
| 700 | 1 | _ | |a Klopfenstein, Quentin |b 89 |e Contributor |
| 700 | 1 | _ | |a Klucken, Jochen |b 90 |e Contributor |
| 700 | 1 | _ | |a Krüger, Rejko |b 91 |e Contributor |
| 700 | 1 | _ | |a Lambert, Pauline |b 92 |e Contributor |
| 700 | 1 | _ | |a Landoulsi, Zied |b 93 |e Contributor |
| 700 | 1 | _ | |a Lentz, Roseline |b 94 |e Contributor |
| 700 | 1 | _ | |a Liepelt-Scarfone, Inga |0 P:(DE-2719)2109499 |b 95 |e Contributor |u dzne |
| 700 | 1 | _ | |a Liszka, Robert |b 96 |e Contributor |
| 700 | 1 | _ | |a Longhino, Laura |b 97 |e Contributor |
| 700 | 1 | _ | |a Lorentz, Victoria |b 98 |e Contributor |
| 700 | 1 | _ | |a Lupu, Paula Cristina |b 99 |e Contributor |
| 700 | 1 | _ | |a Marques, Tainá M |b 100 |e Contributor |
| 700 | 1 | _ | |a Mackay, Clare |b 101 |e Contributor |
| 700 | 1 | _ | |a Maetzler, Walter |b 102 |e Contributor |
| 700 | 1 | _ | |a Marcus, Katrin |b 103 |e Contributor |
| 700 | 1 | _ | |a Marques, Guilherme |b 104 |e Contributor |
| 700 | 1 | _ | |a Conde, Patricia Martins |b 105 |e Contributor |
| 700 | 1 | _ | |a May, Patrick |b 106 |e Contributor |
| 700 | 1 | _ | |a Mcintyre, Deborah |b 107 |e Contributor |
| 700 | 1 | _ | |a Mediouni, Chouaib |b 108 |e Contributor |
| 700 | 1 | _ | |a Meisch, Francoise |b 109 |e Contributor |
| 700 | 1 | _ | |a Menster, Myriam |b 110 |e Contributor |
| 700 | 1 | _ | |a Minelli, Maura |b 111 |e Contributor |
| 700 | 1 | _ | |a Mittelbronn, Michel |b 112 |e Contributor |
| 700 | 1 | _ | |a Mollenhauer, Brit |0 P:(DE-2719)9001340 |b 113 |e Contributor |u dzne |
| 700 | 1 | _ | |a Mühlschlegel, Friedrich |b 114 |e Contributor |
| 700 | 1 | _ | |a Nati, Romain |b 115 |e Contributor |
| 700 | 1 | _ | |a Nehrbass, Ulf |b 116 |e Contributor |
| 700 | 1 | _ | |a Nickels, Sarah |b 117 |e Contributor |
| 700 | 1 | _ | |a Nicolai, Beatrice |b 118 |e Contributor |
| 700 | 1 | _ | |a Nicolay, Jean-Paul |b 119 |e Contributor |
| 700 | 1 | _ | |a Noor, Fozia |b 120 |e Contributor |
| 700 | 1 | _ | |a Ostaszewski, Marek |b 121 |e Contributor |
| 700 | 1 | _ | |a Gomes, Clarissa P C |b 122 |e Contributor |
| 700 | 1 | _ | |a Pachchek, Sinthuja |b 123 |e Contributor |
| 700 | 1 | _ | |a Pauly, Claire |b 124 |e Contributor |
| 700 | 1 | _ | |a Pauly, Laure |b 125 |e Contributor |
| 700 | 1 | _ | |a Pavelka, Lukas |b 126 |e Contributor |
| 700 | 1 | _ | |a Perquin, Magali |b 127 |e Contributor |
| 700 | 1 | _ | |a Lima, Rosalina Ramos |b 128 |e Contributor |
| 700 | 1 | _ | |a Rauschenberger, Armin |b 129 |e Contributor |
| 700 | 1 | _ | |a Rawal, Rajesh |b 130 |e Contributor |
| 700 | 1 | _ | |a Bobbili, Dheeraj Reddy |b 131 |e Contributor |
| 700 | 1 | _ | |a Roomp, Kirsten |b 132 |e Contributor |
| 700 | 1 | _ | |a Rosales, Eduardo |b 133 |e Contributor |
| 700 | 1 | _ | |a Rosety, Isabel |b 134 |e Contributor |
| 700 | 1 | _ | |a Sandt, Estelle |b 135 |e Contributor |
| 700 | 1 | _ | |a Sapienza, Stefano |b 136 |e Contributor |
| 700 | 1 | _ | |a Satagopam, Venkata |b 137 |e Contributor |
| 700 | 1 | _ | |a Schmitt, Margaux |b 138 |e Contributor |
| 700 | 1 | _ | |a Schmitz, Sabine |b 139 |e Contributor |
| 700 | 1 | _ | |a Schneide, Reinhard |b 140 |e Contributor |
| 700 | 1 | _ | |a Schwamborn, Jens |b 141 |e Contributor |
| 700 | 1 | _ | |a Sharify, Amir |b 142 |e Contributor |
| 700 | 1 | _ | |a Soboleva, Ekaterina |b 143 |e Contributor |
| 700 | 1 | _ | |a Sokolowska, Kate |b 144 |e Contributor |
| 700 | 1 | _ | |a Thien, Hermann |b 145 |e Contributor |
| 700 | 1 | _ | |a Thiry, Elodie |b 146 |e Contributor |
| 700 | 1 | _ | |a Loo, Rebecca Ting Jiin |b 147 |e Contributor |
| 700 | 1 | _ | |a Trefois, Christophe |b 148 |e Contributor |
| 700 | 1 | _ | |a Trouet, Johanna |b 149 |e Contributor |
| 700 | 1 | _ | |a Tsurkalenko, Olena |b 150 |e Contributor |
| 700 | 1 | _ | |a Vaillant, Michel |b 151 |e Contributor |
| 700 | 1 | _ | |a Valenti, Mesele |b 152 |e Contributor |
| 700 | 1 | _ | |a Van Cutsem, Gilles |b 153 |e Contributor |
| 700 | 1 | _ | |a Vega, Carlos |b 154 |e Contributor |
| 700 | 1 | _ | |a Boas, Liliana Vilas |b 155 |e Contributor |
| 700 | 1 | _ | |a Vyas, Maharshi |b 156 |e Contributor |
| 700 | 1 | _ | |a Wade-Martins, Richard |b 157 |e Contributor |
| 700 | 1 | _ | |a Wilmes, Paul |b 158 |e Contributor |
| 700 | 1 | _ | |a Wollscheid-Lengeling, Evi |b 159 |e Contributor |
| 700 | 1 | _ | |a Zelimkhanov, Gelani |b 160 |e Contributor |
| 773 | _ | _ | |a 10.1002/mds.29960 |g Vol. 39, no. 10, p. 1773 - 1783 |0 PERI:(DE-600)2041249-6 |n 10 |p 1773 - 1783 |t Movement disorders |v 39 |y 2024 |x 0885-3185 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/272822/files/DZNE-2024-01240.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/272822/files/DZNE-2024-01240.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:272822 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2810728 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 54 |6 P:(DE-2719)2811916 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 64 |6 P:(DE-2719)2320009 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 78 |6 P:(DE-2719)2000008 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 95 |6 P:(DE-2719)2109499 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 113 |6 P:(DE-2719)9001340 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-354 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Prevention and Healthy Aging |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-24 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOVEMENT DISORD : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOVEMENT DISORD : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-2719)1210002 |k AG Heutink |l Genome Biology of Neurodegenerative Diseases |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1210002 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|